COVID-19 Global Pandemic Fight by Drugs: A Mini-Review on Hope and Hype
- 1 June 2022
- journal article
- review article
- Published by Bentham Science Publishers Ltd. in Mini-Reviews in Organic Chemistry
- Vol. 19 (4) , 439-450
Abstract
: Coronavirus disease 2019 (Covid-19), a serious disease caused by the Severe Acute Respiratory Syndrome-Corona Virus-2 (SARS-CoV-2), was firstly identified in the city of Wuhan of China in December 2019, which then spread and became a global issue due to its high transmission rate. To date, the outbreak of COVID-19 has resulted in infection to 230,868,745 people and the death of 4,732,669 patients. It has paralyzed the economy of all the countries worldwide. Considering the possible mutations of SARS-CoV-2, the current medical emergency requires a longer time for drug design and vaccine development. Drug repurposing is a promising option for potent therapeutics against the pandemic. The present review encompasses various drugs or appropriate combinations of already FDA-approved antimalarial, antiviral, anticancer, anti-inflammatory, and antibiotic therapeutic candidates for use in the clinical trials as a ray of hope against COVID-19. It is expected to deliver better clinical and laboratory outcomes of drugs as a prevention strategy for the eradication of the disease.Keywords
This publication has 97 references indexed in Scilit:
- Treating COVID-19—Off-Label Drug Use, Compassionate Use, and Randomized Clinical Trials During PandemicsJAMA, 2020
- Employing drug delivery strategies to create safe and effective pharmaceuticals for COVID‐19Bioengineering & Translational Medicine, 2020
- Supporting the Health Care Workforce During the COVID-19 Global EpidemicJAMA, 2020
- Tocilizumab treatment in COVID‐19: A single center experienceJournal of Medical Virology, 2020
- Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19)JAMA, 2020
- Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS‐CoV, MERS‐CoV, and 2019‐nCoVJournal of Medical Virology, 2020
- Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III StudyArthritis & Rheumatology, 2015
- Upper respiratory tract infectionsIndian Journal of Pediatrics, 2001
- Coronavirus Spike Proteins in Viral Entry and PathogenesisVirology, 2001
- Selection of Novel Analogs of Thalidomide with Enhanced Tumor Necrosis Factor α Inhibitory ActivityMolecular Medicine, 1996